SC-514 is primarily used in research settings as a selective inhibitor of IkappaB kinase-2 (IKK-2), a key enzyme involved in the activation of the NF-κB signaling pathway. This pathway plays a central role in regulating the expression of genes associated with inflammation, immune responses, and cell survival. By inhibiting IKK-2, SC-514 helps suppress the activation of NF-κB, making it a valuable tool for studying inflammatory processes and potential therapeutic targets. It is commonly applied in cellular and molecular studies to investigate the role of NF-κB in diseases such as rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory conditions. Researchers use SC-514 to dissect signaling pathways and evaluate the downstream effects of IKK-2 inhibition, including reduced production of pro-inflammatory cytokines like TNF-α and IL-6. Due to its specificity, SC-514 supports the development and validation of anti-inflammatory drugs, although it is not used clinically. Its application remains confined to laboratory research, particularly in pharmacology and immunology, where understanding the mechanics of inflammation is critical.